Skip to main content
IMS Events Main banner

  1. Home

  • Wednesday, Sep 25th
    6:00 PM – 6:20 PM East Coast USA Time
    P-103: Real World Data on Efficacy and Safety of Low-Dose Direct Oral Anticoagulants (DOACs) for Venous Thromboembolism (VTE) Prophylaxis in Newly Diagnosed Multiple Myeloma
    Location: Station 2, Exhibit Hall, Pavilion 3
    Discussant: Andrew J. Yee, MD – Massachusetts General Hospital Cancer Center
    Poster Presenter: Diana Basali, MD – Cleveland Clinic
    Poster Discussion
  • Wednesday, Sep 25th
    6:00 PM – 6:20 PM East Coast USA Time
    P-112: Fall risk assessment and fall prevention in patients with multiple myeloma: first results of the MYFALL-trial
    Location: Station 1, Exhibit Hall, Pavilion 3
    Discussant: Rafat Abonour, Professor – Indiana University School of Medicine
    Poster Presenter: Ulrike Dapunt, MD – Internal Medicine V, GMMG-Study Group at University Hospital Heidelberg, Heidelberg, Germany
    Poster Discussion
  • Wednesday, Sep 25th
    6:00 PM – 6:20 PM East Coast USA Time
    P-381: Talquetamab Utilization Patterns and Dose Schedules in the United States: A Real-World Analysis
    Location: Station 4, Exhibit Hall, Pavilion 3
    Discussant: P.Joy Ho, MBBS DPhil FRACP FRCPA – Institute of Haematology, Royal Prince Alfred Hospital
    Poster Presenter: Rahul Banerjee, MD (he/him/his) – Fred Hutchinson Cancer Center
    Poster Discussion
  • Wednesday, Sep 25th
    6:20 PM – 6:40 PM East Coast USA Time
    P:113 -An artificial intelligence-based 3D-segmentation assessment of sarcopenia utilizing whole-body computed tomography in patients with multiple myeloma
    Location: Station 1, Exhibit Hall, Pavilion 3
    Discussant: Rafat Abonour, Professor – Indiana University School of Medicine
    Poster Presenter: Ulrike Dapunt, MD – Internal Medicine V, GMMG-Study Group at University Hospital Heidelberg, Heidelberg, Germany
    Poster Discussion
  • Wednesday, Sep 25th
    6:20 PM – 6:40 PM East Coast USA Time
    P-356: Prognostic impact of t(11;14) in newly diagnosed patients with multiple myeloma
    Location: Station 4, Exhibit Hall, Pavilion 3
    Discussant: P.Joy Ho, MBBS DPhil FRACP FRCPA – Institute of Haematology, Royal Prince Alfred Hospital
    Poster Presenter: Ioannis Ntanasis-Stathopoulos, MD, MSc, PhD – Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Greece
    Poster Discussion
  • Wednesday, Sep 25th
    6:20 PM – 6:40 PM East Coast USA Time
    P-408: Survival Analysis of Selinexor-Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Real-World Exploratory Analysis
    Location: Station 3, Exhibit Hall, Pavilion 3
    Discussant: Diana Cirstea
    Poster Presenter: Tommer Mark
    Poster Discussion
  • Wednesday, Sep 25th
    6:20 PM – 6:40 PM East Coast USA Time
    P-426: Isatuximab, plus bortezomib, lenalidomide, and dexamethasone (VRd) for newly diagnosed multiple myeloma (NDMM) transplant-ineligible patients: frailty subgroup analysis of IMROZ
    Location: Station 2, Exhibit Hall, Pavilion 3
    Poster Presenter: Salomon Manier, MD, PhD – Lille University Hospital
    Discussant: Andrew J. Yee, MD – Massachusetts General Hospital Cancer Center
    Poster Discussion
  • Wednesday, Sep 25th
    6:40 PM – 7:00 PM East Coast USA Time
    P-105: PET/CT has prognostic significance for CAR T cell therapy in relapsed/refractory multiple myeloma
    Location: Station 1, Exhibit Hall, Pavilion 3
    Discussant: Rafat Abonour, Professor – Indiana University School of Medicine
    Poster Presenter: Patrick Born (he/him/his) – University Leipzig Medical Center, Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases, Leipzig, Germany
    Poster Discussion
  • Wednesday, Sep 25th
    6:40 PM – 7:00 PM East Coast USA Time
    P-150 Rapid whole-body PET/MRI with fat-suppressed T2-weighted imaging is superior to whole-body PET/MRI with diffusion-weighted imaging (DWI) in plasma cell disorders
    Location: Station 2, Exhibit Hall, Pavilion 3
    Discussant: Andrew J. Yee, MD – Massachusetts General Hospital Cancer Center
    Poster Presenter: Timothy M. Schmidt, MD (he/him/his) – University of Wisconsin
    Poster Discussion
  • Wednesday, Sep 25th
    6:40 PM – 7:00 PM East Coast USA Time
    P-409: Real-Life Outcomes in Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Carfilzomib- and/or Pomalidomide-Based Regimens in the LocoMMotion and MoMMent Studies
    Location: Station 3, Exhibit Hall, Pavilion 3
    Discussant: Diana Cirstea
    Poster Presenter: María-Victoria Mateos, MD, PhD – University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain
    Poster Discussion
  • Friday, Sep 27th
    6:30 PM – 6:50 PM East Coast USA Time
    P-039: CMV Reactivation During Treatment with Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma
    Location: Station 1, Exhibit Hall, Pavilion 3
    Discussant: Efstathios Kastritis, MD, PhD (he/him/his) – Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
    Poster Presenter: Eric M. Jurgens, MD – Department of Medicine, Memorial Sloan Kettering Cancer Center
    Poster Discussion
  • Friday, Sep 27th
    6:30 PM – 6:50 PM East Coast USA Time
    P-084: Efficacy of linvoseltamab in prespecified high risk subgroups of patients with relapsed/refractory multiple myeloma: Results from LINKER-MM1
    Location: Station 2, Exhibit Hall, Pavilion 3
    Discussant: Noa Biran, MD (she/her/hers) – Hackensack Meridian Health School of Medicine; The John Theurer Cancer Center
    Poster Presenter: Attaya Suvannasankha, MD – Indiana University Simon Cancer Center and Roudebush VAMC, Indianapolis, IN, USA
    Poster Discussion
  • Friday, Sep 27th
    6:30 PM – 6:50 PM East Coast USA Time
    P-232: Comprehensive genomic sequencing predicts sub-optimal response to bispecific antibodies (BsAb) and chimeric antigen receptor T cells (CAR-T) in multiple myeloma (MM)
    Location: Station 4, Exhibit Hall, Pavilion 3
    Discussant: Lugui Qiu, MD (he/him/his) – Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.
    Poster Presenter: Kylee Maclachlan, MBChB, PhD – Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City NY, USA
    Poster Discussion
  • Friday, Sep 27th
    6:30 PM – 6:50 PM East Coast USA Time
    P-252: Critical roles of LILRB4 in promoting STAT3/PIM1 mediated metabolism in multiple myeloma
    Location: Station 3, Exhibit Hall, Pavilion 3
    Poster Presenter: yijie wang – State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
    Discussant: Adam S. Sperling, MD, PhD (he/him/his) – Brigham and Women's Hospital
    Poster Discussion
  • Friday, Sep 27th
    6:50 PM – 7:10 PM East Coast USA Time
    P-183: MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE (MGUS) LIKE PROFILE IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (MM) PATIENTS: CLINIC-BIOLOGICAL CHARACTERISTICS AND PROGNOSIS SIGNIFICANCE
    Location: Station 4, Exhibit Hall, Pavilion 3
    Discussant: Lugui Qiu, MD (he/him/his) – Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.
    Poster Presenter: Borja Puertas (he/him/his) – Hospital Universitario de Salamanca
    Poster Discussion
  • Friday, Sep 27th
    6:50 PM – 7:10 PM East Coast USA Time
    P-264: Mezigdomide (MEZI) reverses T-cell exhaustion (Tex) through degradation of Aiolos/Ikaros and reinvigoration of cytokine production pathways
    Location: Station 2, Exhibit Hall, Pavilion 3
    Discussant: Noa Biran, MD (she/her/hers) – Hackensack Meridian Health School of Medicine; The John Theurer Cancer Center
    Poster Presenter: Nathan Martin, PhD (he/him/his) – Bristol Myers Squibb
    Poster Discussion
  • Friday, Sep 27th
    6:50 PM – 7:10 PM East Coast USA Time
    P-270: Alternative Splicing and Non-Homologous End Joining Pathways Are Vulnerabilities Associated With Loss of The Tumor Suppressor TENT5C in Myeloma
    Location: Station 1, Exhibit Hall, Pavilion 3
    Discussant: Efstathios Kastritis, MD, PhD (he/him/his) – Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
    Poster Presenter: Oumaima Jaouadi, Ph.D – Melvin and Bren Simon Comprehensive Cancer Center
    Poster Discussion
  • Friday, Sep 27th
    6:50 PM – 7:10 PM East Coast USA Time
    P-427: REAL-WORLD PREVALENCE AND MULTI-OMIC ANALYSIS OF T(11;14)-POSITIVE MULTIPLE MYELOMA: FINAL ANALYSIS FROM THE MEDICI STUDY
    Location: Station 3, Exhibit Hall, Pavilion 3
    Discussant: Adam S. Sperling, MD, PhD (he/him/his) – Brigham and Women's Hospital
    Poster Presenter: Andrew Spencer, MBBS FRACP, FRCPA, DM – Alfred Health-Monash University
    Poster Discussion
  • Friday, Sep 27th
    7:10 PM – 7:30 PM East Coast USA Time
    P-165: Advanced circulating tumor DNA (ctDNA)Profiling: Enhancing Non-Invasive Detection and Characterization of Measurable Residual Disease (MRD) in Multiple Myeloma (MM)
    Location: Station 3, Exhibit Hall, Pavilion 3
    Discussant: Adam S. Sperling, MD, PhD (he/him/his) – Brigham and Women's Hospital
    Poster Presenter: Natalia Buenache – Hospital Universitario 12 Octubre
    Poster Discussion
  • Friday, Sep 27th
    7:10 PM – 7:30 PM East Coast USA Time
    P-263: Disrupting the lysosome and autophagy via PIKfyve inhibition is a potential novel therapeutic approach in Multiple Myeloma
    Location: Station 2, Exhibit Hall, Pavilion 3
    Discussant: Noa Biran, MD (she/her/hers) – Hackensack Meridian Health School of Medicine; The John Theurer Cancer Center
    Poster Presenter: Cecilia Bonolo de Campos, MSc PhD – Princess Margaret Cancer Center - UHN
    Poster Discussion
  • Friday, Sep 27th
    7:10 PM – 7:30 PM East Coast USA Time
    P-302: Correlative Analysis Between the 20-2-20 Score and 3D Telomere Profiling in Stratifying Smouldering Myeloma Patientss
    Location: Station 1, Exhibit Hall, Pavilion 3
    Discussant: Efstathios Kastritis, MD, PhD (he/him/his) – Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
    Poster Presenter: Shaji K. Kumar, MD – Mayo Clinic, Rochester, MN, US
    Poster Discussion